GC Biopharma is set to report a substantial boost in its third-quarter earnings, driven by the U.S. launch of its immune globulin product, Alyglo, for the treatment of primary immunodeficiency. Sales for the quarter are projected to reach around 20 billion won (US$15.3 million), with full-year revenue expected to total 60 billion won (US$45.9 million), according to industry reports.
Alyglo gained FDA approval in December 2023, and the company has rapidly scaled its U.S. presence. Key to this success is its inclusion in the formularies of three major U.S. insurance providers, which ensures reimbursement coverage and facilitates wider patient access. GC Biopharma has also secured contracts with pharmacy benefit managers (PBMs) and specialty pharmacies, further strengthening its distribution network.
With demand increasing since the product began treating U.S. patients in August, the company has shipped multiple batches and is focused on maintaining consistent supply to meet market needs. This expansion into the U.S. market highlights GC Biopharma’s efforts to capitalize on the robust growth potential of the immune globulin market.
